Rigel Pharmaceuticals, Inc.

RIGL · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders3.4%

Institutions89.3%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$294.28M	$179.28M	$116.88M	$120.24M	$149.24M	$108.62M	$59.29M	$44.51M	–	–
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$19.62M	$18.65M	$7.11M	$1.75M	$1.08M	$895000	$906000	$287000	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	$125.47M	$24.19M	-$20.49M	-$55.55M	-$12.50M	-$28.97M	-$69.09M	-$72.68M	-$79.62M	-$69.74M
Operating income as a percentage of revenue.	42.6%	13.5%	-17.5%	-46.2%	-8.4%	-26.7%	-116.5%	-163.3%	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$367.02M	$17.48M	-$25.09M	-$58.57M	-$17.91M	-$29.74M	-$66.89M	-$70.48M	-$77.99M	-$69.22M
Net income divided by the number of shares outstanding — profit attributable to each share.	$20.40	$0.99	$0.00	$0.00	$-0.11	$-0.18	$-0.40	$-0.44	$0.00	$0.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$19.48	$0.99	$0.00	$0.00	$-0.11	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$40.58M	$56.75M	$32.79M	$24.46M	$18.89M	$30.37M	$22.52M	$76.32M	$38.29M	$17.63M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$513.59M	$163.98M	$117.22M	$134.28M	$167.33M	$110.38M	$147.57M	$139.11M	$119.11M	$78.13M
Everything the company owes — debt, unpaid bills, and other obligations.	$122.11M	$160.69M	$145.87M	$147.90M	–	–	–	–	–	–
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$391.48M	$3.29M	-$28.64M	-$13.62M	$30.37M	$34.03M	$53.81M	$109.88M	$100.65M	$55.03M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$75.66M	$31.47M	-$5.74M	-$73.76M	$5.88M	-$52.19M	-$41.51M	-$58.83M	-$77.56M	-$75.89M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	–	–	–	$450000	$627000	$1.26M	$1.46M	$1.11M	$164000	$804000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	–	–	–	-$74.21M	$5.25M	-$53.45M	-$42.97M	-$59.93M	-$77.72M	-$76.69M

	You	Peer avg
P/E	2.9	–
Revenue Growth	-22.6%	+23.8%
ROE	126.9%	-57.7%

Rigel Pharmaceuticals, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison